Skip to content

Face Masks to Reduce SARS-CoV-2 Infections (COVID-19) in Bangladesh

Face Masks to Reduce Symptomatic and Asymptomatic SARS-CoV-2 Infections in Bangladesh

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05197725
Enrollment
0
Registered
2022-01-19
Start date
2023-02-04
Completion date
2023-05-30
Last updated
2023-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

Masks, Transmission, Bangladesh, Behavioral psychology

Brief summary

The primary goal of the village-level intervention is to assess whether mask-wearing reduces community-level asymptomatic and symptomatic SARS-CoV-2 infections, assessed via PCR testing. The study also examines if community-based activation through values or individual activation through information results in higher mask-wearing.

Detailed description

Detailed Description: This study intends to answer the following research questions: Can mask distribution and mask promotion at homes, mosques, markets and other public areas successfully change community mask-wearing norms to increase mask-wearing, even years into a pandemic? Can community mask-wearing reduce SARS-CoV-2 infections (both symptomatic and asymptomatic)? Is increased prevalence of community-level mask-wearing associated with decreased physical distancing? To answer these questions, the investigators will conduct a cluster randomized trial which randomizes the proposed intervention at the village level in Bangladesh. Control communities will receive no intervention and treatment communities will receive an extensive intervention combining several elements. Study staff will distribute free face masks through door-to-door visits and at markets and mosques. In some communities groups of people will be encouraged to wear masks by appealing to their shared values and in other communities individuals will be encouraged to wear masks by discussing the biological value of masks (cross-randomized among intervention communities). Mask promoters in the community and at markets in treated villages will remind people about the importance of wearing masks and distribute additional masks. Markets will have signs that masks need to be worn to enter the market. Religious leaders will encourage mask use at religious services. The project will enroll 1200 communities, stratified in geographically proximate groups of 10; half will be randomized to receive the intervention. Communities will be surveilled through direct observation at 0, 2, and 4 weeks to assess mask-wearing. The investigators will assess symptomatic and asymptomatic SARS-CoV-2 by conducting household visits every 6-10 days to ask about symptoms of COVID-19 and collecting nasal swabs to test by PCR for the presence of SARS-CoV-2. End line is planned for 4 weeks after the intervention begins, but may be shifted according to seroprevalence trends.

Interventions

DEVICEFace mask

Individuals in intervention communities will be given surgical or KF94 face masks.

Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.

BEHAVIORALFace mask promotion through community values or individual information

In intervention communities randomized to mask promotion through community values, promotional discussions and media will focus on encouraging groups of people to wear masks as a reflection of their values. In intervention communities randomized to mask promotion through individual information, promotional discussions and media will target individuals and focus on the instrumental value of wearing masks (preventing the inhalation of viral particles)

Sponsors

Stanford University
CollaboratorOTHER
University of California, Berkeley
CollaboratorOTHER
Innovations for Poverty Action
CollaboratorOTHER
North South University
CollaboratorOTHER
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Masking description

The intervention involves wearing a face mask so participants will know if they are in the intervention group. The investigators will be blinded as to intervention assignment.

Intervention model description

This is a randomized controlled trial with an equal number of intervention and control villages enrolled each day.

Eligibility

Sex/Gender
FEMALE
Age
12 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Live in selected village

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Asymptomatic and asymptomatic SARS-CoV-2 infectionapproximately weekly for 4 weeks; may be lengthened if the intervention is extended due to low than estimated seroprevalence at the start of the interventionAsymptomatic and asymptomatic SARS-CoV-2 infection, assessed using PCR testing every 6-10 days after baseline, among individuals regardless of whether they report symptoms of COVID-19

Secondary

MeasureTime frameDescription
Observed prevalence of mask-wearingIntervention weeks 0, 2, and 4; end line and midline timepoints may be adjusted if the intervention is extended due to low than estimated seroprevalence at the start of the intervention.Percent of people observed in public places wearing a mask over their mouth and nose compared to wearing a mask or face covering that does not cover the mouth and nose or not wearing any mask or face covering. The investigators will include sub-group analyses by age group, gender, and location
Respiratory infection prevalenceapproximately weekly for 4 weeks; may be lengthened if the intervention is extended due to low than estimated seroprevalence at the start of the interventionPrevalence of self-reported symptoms of COVID-19, including fever, cough, sore throat, shortness of breath, difficulty breathing, nasal congestion, and runny nose.
Physical distancingIntervention weeks 0, 2, and 4; end line and midline timepoints may be adjusted if the intervention is extended due to low than estimated seroprevalence at the start of the intervention.Prevalence of physical distancing among observed individuals wearing or not wearing a mask

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026